Oxidative Stress in Leukemia: How Imbalanced Free Radicals Fuel Disease and New Antioxidant Solutions
Leukemia, a cancer of the blood and bone marrow, affects millions of people worldwide—including children, who are most often diagnosed with acute lymphoblastic leukemia (ALL). While chemotherapy and targeted drugs have improved survival rates, many patients still face relapse or treatment resistance. But a growing body of research points to a hidden player in leukemia’s development and progression: oxidative stress. Here’s what you need to know about how imbalanced free radicals impact leukemia—and the promising antioxidant therapies being explored to fight it.
What Is Oxidative Stress?
To understand oxidative stress, start with reactive oxygen species (ROS)—molecules like superoxide ions and hydrogen peroxide produced naturally by cell metabolism (e.g., from mitochondria, the cell’s “power plants”). In healthy cells, antioxidants (enzymes like superoxide dismutase or vitamins like C and E) keep ROS in check. But when ROS levels spike or antioxidant defenses weaken, the balance tips: excess ROS damages DNA, proteins, and lipids, triggering inflammation, cell death, or even mutations that drive cancer. This is oxidative stress.
How Oxidative Stress Fuels Leukemia
Leukemia begins in hematopoietic stem cells (HSCs)—adult stem cells in bone marrow that make all blood cells. HSCs are uniquely sensitive to ROS: they normally live in “niches” with low ROS levels to stay healthy. But chronic oxidative stress (from factors like radiation, chemicals, or gene mutations) can:
- Damage HSCs: High ROS levels cause DNA mutations, senescence (cell aging), or apoptosis (programmed cell death) in HSCs.
- Disrupt the HSC Niche: ROS alters the bone marrow environment, making it harder for healthy HSCs to grow and differentiate.
- Drive Malignant Transformation: Mutated HSCs that survive oxidative stress can become leukemia stem cells (LSCs)—the “root” of leukemia that resists treatment and causes relapse.
For example, in chronic myeloid leukemia (CML), the abnormal BCR-ABL fusion gene (a hallmark of the disease) boosts ROS production by activating enzymes like NADPH oxidase. High ROS levels not only damage cells but also make BCR-ABL more likely to mutate—leading to treatment resistance with drugs like imatinib.
Oxidative Stress in Different Leukemias
Leukemia is grouped into four main types based on cell type (myeloid vs. lymphoid) and progression (acute vs. chronic). Here’s how oxidative stress plays a role in each:
1. Acute Myeloid Leukemia (AML)
AML is the most common acute leukemia in adults, characterized by fast-growing immature myeloid cells. Traditional treatments include intensive chemotherapy, stem cell transplants, and immunotherapy—but only ~20% of adults achieve long-term survival.
Oxidative stress drives AML in two key ways:
- Relapse Risk: High ROS levels correlate with higher relapse rates, as LSCs use antioxidants to survive treatment.
- Therapy Resistance: The transcription factor Nrf2 (which controls antioxidant genes) is overactive in AML, helping cells resist chemotherapy.
Promising antioxidant approaches:
- Arsenic Trioxide (ATO): A pro-oxidant drug that works for acute promyelocytic leukemia (APL), a curable AML subtype. ATO increases ROS to kill cancer cells.
- Histamine Dihydrochloride (HDC) + IL-2: A combination that reduces ROS in immune cells, lowering relapse risk in AML patients who’ve had chemotherapy.
2. Chronic Myeloid Leukemia (CML)
CML starts slowly but can progress to a fatal acute phase. The BCR-ABL gene is its main driver, and tyrosine kinase inhibitors (TKIs) like imatinib are first-line treatments. However, ROS-driven mutations in BCR-ABL often cause resistance.
Oxidative stress therapies:
- Ivermectin: An antibiotic that targets mitochondria in CML cells, increasing ROS and triggering cell death.
- Vitamin A: Combined with standard chemotherapy, it extends survival in CML patients.
3. Acute Lymphoblastic Leukemia (ALL)
ALL is the most common childhood leukemia, affecting B or T cells. While chemotherapy cures ~90% of kids, relapse and long-term side effects are major concerns.
Oxidative stress links:
- MDSCs: Immune cells called myeloid-derived suppressor cells (MDSCs) use ROS to suppress anti-leukemia immunity. Targeting MDSCs could boost treatment effectiveness.
- Natural Compounds: Snake venom-derived L-amino acid oxidase (LAAO) kills T-ALL cells by increasing hydrogen peroxide (H₂O₂).
4. Chronic Lymphocytic Leukemia (CLL)
CLL is a slow-growing cancer of mature B cells, common in older adults. Traditional treatments are palliative, but oxidative stress offers new hope:
- Acacetin: A flavonoid from plants that selectively kills CLL cells by targeting “cancerous mitochondria” and increasing ROS.
- Lenalidomide: A drug that modulates the immune system and reduces oxidative stress in CLL.
Antioxidant Therapies: From Vitamins to Targeted Drugs
Antioxidants work by balancing ROS levels—either by scavenging excess free radicals or boosting the body’s natural defense systems. Here are the most promising types for leukemia:
1. Vitamin Antioxidants
Vitamins C and D3 enhance the effects of ATO in APL:
- Vitamin D3: Makes ATO more toxic to AML cells (e.g., HL-60 cells).
- Vitamin C + D3 + ATO: A potential combination therapy for APL that reduces oxidative stress and kills cancer cells.
Vitamin E also helps protect healthy cells from chemotherapy-induced ROS damage.
2. Natural Plant-Derived Antioxidants
Many plants have compounds that fight leukemia without harming healthy cells:
- Moringa oleifera: Leaf extract protects APL cells from oxidative damage and increases viability at specific doses.
- Curcumin/Resveratrol: These well-known antioxidants reduce ROS in leukemia cells and sensitize them to chemotherapy.
- Tetrandrine: A compound from the Chinese herb Stephania tetrandra induces autophagy (cell “cleanup”) in leukemia cells, triggering apoptosis.
3. Intracellular Antioxidants
Cells have their own antioxidant systems—targeting these can help kill LSCs:
- Glutathione (GSH): A key intracellular antioxidant. Drugs that deplete GSH (like isothiocyanates) kill chemotherapy-resistant CLL and CML cells.
- Heme Oxygenase-1 (HO-1): A protein that reduces oxidative stress. Inhibiting HO-1 makes AML cells more sensitive to treatment.
4. Targeted Oxidative Stress Drugs
New drugs directly target ROS or its pathways:
- ATO: As mentioned, a pro-oxidant that works for APL by increasing ROS and inhibiting antioxidant systems.
- Ruxolitinib: A JAK2 inhibitor that combines with ATO to increase ROS and DNA damage in AML cells.
The Future of Oxidative Stress Treatments: Hope and Limitations
Antioxidant therapies hold great promise for leukemia—but they’re not a “magic bullet.” Key challenges include:
- Lack of Large Trials: Most antioxidant treatments are in early stages; large, multicenter studies are needed to prove their safety and effectiveness.
- ROS as a Double-Edged Sword: Low ROS levels help cancer cells grow, but high ROS kills them. Finding the “sweet spot” for treatment is tricky.
- Personalization: Oxidative stress levels vary by patient—future therapies will need to be tailored to individual genetics and disease subtypes.
Conclusion
Oxidative stress is more than just a “side effect” of leukemia—it’s a driver of disease development, treatment resistance, and relapse. The work of researchers like Chao Dong, Nai-Jin Zhang, and Li-Jun Zhang (from the First Hospital of China Medical University) is shedding light on how to target this imbalance with antioxidants and pro-oxidants alike. While challenges remain, these therapies offer new hope for patients who’ve exhausted traditional options.
If you or a loved one is affected by leukemia, talk to your doctor about emerging oxidative stress treatments—every advance brings us closer to better outcomes.
For more details on the original research, see the study published in Chinese Medical Journal (2021) by Dong C, Zhang NJ, Zhang LJ. doi.org/10.1097/CM9.0000000000001628
Was this helpful?
0 / 0